Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients

Acta Cardiologica

Volumn 64, Issue 4, 2009, Pages 485-491

  Spoladore, Roberto ^a   Roccaforte, Rosa ^a   Fragasso, Gabriele ^a   Gardini, Chiara ^a   Palloshi, Altin ^a   Cuko, Amarild ^a   Arioli, Francesco ^a   Salerno, Anna ^a   Margonato, Alberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Antihypertensive therapy; Doxazosin; Heart failure; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN;

ADD ON THERAPY; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; DOXAZOSIN; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPERTENSION; MALE; STROKE VOLUME;

EID: 69249147910     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.64.4.2041613     Document Type: Article

References (22)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283: 1967-1975.
3. Thiyagarajan M. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Pharmacology 2002; 65: 119-128 (Pubitemid 34621746)
4. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398
5. Lasagna L. Diuretics vs. alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2000; 283: 2013-2014 (Pubitemid 30214958)
6. Furberg CD. Doxazosin, an inferior antihypertensive agent? J Hum Hypertens 2002; 16: 375-377
7. Sica DA. Doxazosin and congestive heart failure. Congest Heart Fail 2002; 8:178-184
8. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehega T, Ma J. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA 2004; 291: 54-62.
9. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Piérard L, Remme WJ. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140
10. Geraci JM, Ashton CM, Kuykendall DH, Johnson ML, Wu L. ICD-9-CM. International Classification of Diseases - 9th revision - Clinical Modification - 1997. Med Care 1997; 35: 589-602.
11. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002; 39: 463-470 (Pubitemid 34117504)
12. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM - Overall programme. Lancet 2003; 362: 759-766
13. Roccaforte R, Demers C, Baldassarre F, Teo KK, Yusuf S. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis. Eur J Heart Fail 2005; 7: 1133-1144 (Pubitemid 41721116)
14. Bryson CL, Smith NL, Kuller LH, Chaves PH, Manolio TA, Lewis W, Boyko EJ, Furberg CD, Psaty BM. Risk of congestive heart failure in an elderly population treated with peripheral alpha-1 antagonists. J Am Geriatr Soc 2004; 52: 1648-1654 (Pubitemid 41709917)
15. McAlister FA, Teo KK, Taher M, Montague TJ, Humen D, Cheung L, Kiaii M, Yim R, Armstrong PW Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 1999; 138: 87-94. (Pubitemid 29331126)
16. Ansari M, Alexander M, Tutar A, Massie BM. Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function. Am Heart J 2003; 146: 115-120 (Pubitemid 36851309)
17. Pulignano G, Del Sindaco D, Tavazzi L, Lucci D, Gorini M, Leggio F, Porcu M, Scherillo M, Opasich C, Di Lenarda A, Senni M, Maggioni AP; IN-CHF Investigators. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J 2002; 143: 45-55. (Pubitemid 34056374)
18. McMurray J, Ostergren J, Pfeffer M, Swedberg K, Granger C, Yusuf S, Held P, Michelson E, Olofsson B; CHARM committees and investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003; 5: 261-270 (Pubitemid 37011854)
19. Bouvy ML, Heerdink ER, Leufkens HGM, Hoes AW Patterns of pharmacotherapy in patients hospitalized for congestive heart failure. Eur J Heart Fail 2003; 5: 195-200. (Pubitemid 36383629)
20. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464-474
21. Koukkunen H, Pyörälä K, O Halinen O. Low-risk patients with chest pain and without evidence of myocardial infarction may be safely discharged from emergency department. Eur Heart J 2004; 25: 329-334 (Pubitemid 38295442)
22. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290: 2581-2587 (Pubitemid 37443288)